Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
15 hedge funds and large institutions have $282K invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
6% less funds holding
Funds holding: 16 → 15 (-1)
27% less capital invested
Capital invested by funds: $385K → $282K (-$104K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.47K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$1.02K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$240 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFI
EHP Funds Inc
Toronto,
Canada
|
-$5.61K |
| 2 |
CAC
Cowen and Company
New York
|
-$38 |
| 3 |
6CM
683 Capital Management
New York
|
-$19 |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$3 |
CLDI.WS Hedge Fund Activity: Q2 2024 in Review
15 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q2 2024, worth a combined $282K — down 27% from $385K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CLDI.WS and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, adding an estimated $3.47K. The largest seller was EHP Funds Inc, exiting entirely with an estimated $5.61K sold.
- 15 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q2 2024, down from 16 in Q1 2024.
- Funds reported $282K of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q2 2024, down 27% quarter-over-quarter.
- 1 fund opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q2 2024 and 2 closed out, a net change of -1 holder.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q2 2024 was Citadel Advisors, an estimated $3.47K added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q2 2024 was EHP Funds Inc, an estimated $5.61K sold.
Based on aggregated 13F filings for Q2 2024.